[Skip to Navigation]
Invited Commentary
July 16, 2020

Treatment for a Subtype of Exudative Macular Degeneration—Another Mountain Climbed

Author Affiliations
  • 1Division of Ophthalmology, Department of Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu
  • 2Hawaii Macula and Retina Institute, Aiea
  • 3The Eye Institute, Medical College of Wisconsin, Milwaukee
JAMA Ophthalmol. 2020;138(9):942-944. doi:10.1001/jamaophthalmol.2020.2421

Polypoidal choroidal vasculopathy (PCV) is a subtype of exudative age-related macular degeneration (AMD) that is most prevalent in Asian populations but is becoming increasingly recognized in populations around the world.1-3 The importance of recognizing PCV is that it is a subtype of exudative AMD that has been associated with resistance to antivascular endothelial growth factor (anti-VEGF) injections, which has become standard treatment for most cases of active exudative AMD.1,2 Therefore, finding a good treatment option for PCV would benefit many patients around the world.

Add or change institution